PAUL GAMBINO: Open Payments
NPI 1235427451 · STUART, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$36,990 in 163 payments from 27 companies in 2025. Trend: 2023 $67,963 · 2024 $40,596 · 2025 $36,990
Speaker / faculty: $32,800Food & beverage: $2,782Travel & lodging: $1,408
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 59 | $34,904 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $325 |
| Novartis Pharmaceuticals Corporation | 10 | $207 |
| AstraZeneca Pharmaceuticals LP | 9 | $192 |
| PFIZER INC. | 9 | $179 |
| Novo Nordisk Inc | 11 | $160 |
| GlaxoSmithKline, LLC. | 5 | $107 |
| ABBVIE INC. | 5 | $104 |
| Lilly USA, LLC | 4 | $91 |
| Janssen Pharmaceuticals, Inc | 3 | $91 |
Products named: REPATHA, CAPLYTA, LEQVIO, OTEZLA, NURTEC ODT, AIRSUPRA, TRELEGY ELLIPTA, SPRAVATO.
Industry payments across FL — which companies pay providers there.
